2498-50-2Relevant articles and documents
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform
Pant, Shishir M.,Mukonoweshuro, Amanda,Desai, Bimbisar,Ramjee, Manoj K.,Selway, Christopher N.,Tarver, Gary J.,Wright, Adrian G.,Birchall, Kristian,Chapman, Timothy M.,Tervonen, Topi A.,Klefstr?m, Juha
supporting information, p. 4335 - 4347 (2018/05/14)
Hepsin is a membrane-anchored serine protease whose role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis. Using an integrated design, synthesis, and screening platform, we were able to rapidly develop potent and selective inhibitors of hepsin. In progressing from the initial hit 7 to compound 53, the IC50 value against hepsin was improved from ~1 μM to 22 nM, and the selectivity over urokinase-type plasminogen activator (uPA) was increased from 30-fold to >6000-fold. Subsequent in vitro ADMET profiling and cellular studies confirmed that the leading compounds are useful tools for interrogating the role of hepsin in breast tumorigenesis.
Design, synthesis and structure-activity relationships of novel diaryl urea derivatives as potential EGFR inhibitors
Jiang, Nan,Bu, Yanxin,Wang, Yu,Nie, Minhua,Zhang, Dajun,Zhai, Xin
, (2016/12/03)
Two novel series of diaryl urea derivatives 5a-i and 13a-l were synthesized and evaluated for their cytotoxicity against H-460, HT-29, A549, and MDA-MB-231 cancer cell lines in vitro. Therein, 4-aminoquinazolinyl-diaryl urea derivatives 5a-i demonstrated significant activity, and seven of them are more active than sorafenib, with IC50 values ranging from 0.089 to 5.46 μM. Especially, compound 5a exhibited the most active potency both in cellular (IC50 = 0.15, 0.089, 0.36, and 0.75 μM, respectively) and enzymatic assay (IC50 = 56 nM against EGFR), representing a promising lead for further optimization.
PROCESS FOR THE MANUFACTURE OF 4-AMINOBENZOAMIDINE DIHYDROCHLORIDE
-
Page/Page column 10-11, (2014/05/24)
The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I), preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.